FTY720: Placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 8, 2006, Pages 895-904

  Schmouder, Robert ^a   Serra, Denise ^a   Wang, Yibin ^a   Kovarik, John M ^a   DiMarco, John ^b   Hunt, Thomas L ^c   Bastien, Marie Claude ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

Cardiac rate and rhythm; FTY720; Immunomodulators

Indexed keywords

FINGOLIMOD; IMMUNOMODULATING AGENT; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CHRONOTROPISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALE; NORMAL HUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUPRAVENTRICULAR PREMATURE BEAT; TELEMETRY; TREATMENT DURATION;

ADOLESCENT; ADULT; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROPYLENE GLYCOLS; REFERENCE VALUES; SPHINGOSINE;

EID: 33745927144     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006289853     Document Type: Article

References (22)

1. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing in rats: I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160:5037-5044.
2. Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation. 2001;72:764-769.
3. Brinkmann V, Chen S, Feng L, Pinschewer DD, Nokolova Z, Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc. 2001;33:530-531.
4. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine-1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 2002;14:569-575.
5. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 2000;164:5761-5770.
6. Walker R, Ferguson RM, Mulgaonker S, et al. FTY720 with reduced cyclosporine exposure is efficacious in preventing rejection in renal transplantation: 12-month preliminary results. Presented at: World Congress of Nephrology; June 8-12, 2003; Berlin. Abstract T680.
7. Lorber M, Kahan B, Tedesco H, et al. FTY720 in combination with everolimus: a novel CNI-free regimen effective in patients at high risk for DGF. Presented at: the World Congress of Nephrology; June 8-12, 2003; Berlin. Abstract T679.
8. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073-1083.
9. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation. 2003;76:1079-1084.
10. Liliom K, Sun G, Bunemann M, et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J. 2001;355:189-197.
11. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. 1999;438:642-648.
12. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calm T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 2002;50:661-670.
13. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant. 2005;5:529-536.
14. Ferguson R. FTY720 immunomodulation: optimism for improved transplant regimens. Transplant Proc. 2004;36(Suppl 2):549S-553S.
15. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004;44:532-537.
16. Bruce RA. Methods of exercise testing: step test, bicycle, treadmill, isometrics. Am J Cardiol. 1974;33:715-720.
17. Jardine A, Grinyo JM, Mulgaonkar S, Ferguson RM, Cremer M, Preiss R. FTY720, a sphingosine-1-phosphate receptor agonist, does not elicit adverse effects on cardiac rhythm in renal transplant patients on maintenance therapy. Presented at: American Transplant Congress; May 15-19, 2004; Boston. Abstract 1040.
18. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355-360.
19. Bunemann M, Liliom K, Brandts BK, et al. A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine-1-phosphate in atrial myocytes. EMBO J. 1996;15:5527-5534.
20. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457.
21. Forrest M, Sun SY, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004;309:758-768.
22. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279:13839-13848.